Prostate cancer is the most common form of cancer among men in England, with cases surging by 25 per cent between 2019 and 2023, according to NHS data. It’s also the second-deadliest form of the ...

Prostate-specific antigen (PSA) testing may not accurately pinpoint levels at which transgender women on estrogen therapy may be at risk of developing prostate cancer, according to data from the ...

Screening PSA levels at aged 65-69 may inform the decision to continue or discontinue prostate cancer screening after age 70 years, regardless of patient race and ethnicity. The absolute risks of ...

A new study indicates there is no specific PSA value that has both high sensitivity and high specificity for monitoring healthy men for prostate cancer, but rather there is a continuum of prostate ...

Preoperative platelet-derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation in high-risk localized prostate cancer ...

For decades, it has been known that prostate specific antigen ‒ or PSA ‒ tests are a flawed way to diagnose prostate cancer. Many men have a high PSA without having cancer. Others have low PSA that ...

February 10, 2023 – Declines in prostate-specific antigen (PSA) level after treatment with the next-generation androgen receptor inhibitor drug enzalutamide predict improved survival rates in men with ...

During September’s Prostate Cancer Awareness Month, MidLantic Urology is reminding men of a critical point. It's 0.75. If your PSA increases by 0.75 in 1 year, it could be prostate cancer, and it’s ...

MILAN—One quarter of all men with an initially normal PSA level will be diagnosed with PCa within 16 years, and many will have incurable disease, researchers reported at the 28 th annual European ...

Declines in prostate-specific antigen (PSA) level after treatment with the next-generation androgen receptor inhibitor drug enzalutamide predict improved survival rates in men with non-metastatic ...